Background: The effectiveness of ustekinumab in patients with refractory Crohn’s disease (CD) has been investigated in several real-world studies. However, very few data concerning the real-life experience in Italy have been reported. Therefore, this study assessed the effectiveness of ustekinumab in a large cohort of Italian patients with refractory CD. Methods: All patients who had started on ustekinumab after failure of or intolerance to antitumour necrosis factor-a (TNF-a) treatment at five tertiary centres between November 2018 and February 2020 were retrospectively enrolled. The coprimary outcome was corticosteroid-free clinical remission, defined as a Harvey–Bradshaw Index (HBI) score of !4, at weeks 26 and 52. The secondary outcomes were changes in the HBI and C-reactive protein (CRP) values at weeks 8, 26, and 52 from baseline and the normalization of CRP in patients with initially abnormal values. Results: Totally, 140 patients who had previously received at least one anti-TNF- agent were enrolled; 40.0% received two anti-TNF- agents and 20.0% received vedolizumab. At baseline, 108 patients (77.1%) had HBI scores of >4; of these, 56.5% and 58.3% achieved corticosteroidfree clinical remission at weeks 26 and 52, respectively. Significant decreases in HBI and CRP values were observed at weeks 8, 26, and 52 in the entire study cohort (all p < 0.0001). The CRP values were normalized in 34.9%, 37.8%, and 49.3% of the patients by weeks 8, 26, and 52, respectively. The baseline HBI score of "8 was a negative predictor of corticosteroid-free clinical remission at week 52 (odds ratio: 0.21, 95% confidence interval: 0.08–0.56, p # 0.002). The probability of remaining on ustekinumab after 52 weeks was 92.1%. Eleven (7.9%) patients discontinued ustekinumab (three for adverse events). Conclusion: Our study findings confirm the effectiveness and safety of ustekinumab in patients with CD after failure of or intolerance to anti-TNF-a therapy.

Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy / Lia Scribano, Maria; Aratari, Annalisa; Neri, Benedetto; Bezzio, Cristina; Balestrieri, Paola; Baccolini, Valentina; Falasco, Giuliano; Camastra, Caterina; Pantanella, Paolo; Monterubbianesi, Rita; Tullio, Alessandro; Saibeni, Simone; Papi, Claudio; Biancone, Livia; Cosintino, Rocco; Faggiani, Roberto. - In: THERAPEUTIC ADVANCES IN GASTROENTEROLOGY. - ISSN 1756-283X. - 15:(2022), pp. 1-13. [10.1177/17562848211072412]

Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy

Valentina Baccolini;
2022

Abstract

Background: The effectiveness of ustekinumab in patients with refractory Crohn’s disease (CD) has been investigated in several real-world studies. However, very few data concerning the real-life experience in Italy have been reported. Therefore, this study assessed the effectiveness of ustekinumab in a large cohort of Italian patients with refractory CD. Methods: All patients who had started on ustekinumab after failure of or intolerance to antitumour necrosis factor-a (TNF-a) treatment at five tertiary centres between November 2018 and February 2020 were retrospectively enrolled. The coprimary outcome was corticosteroid-free clinical remission, defined as a Harvey–Bradshaw Index (HBI) score of !4, at weeks 26 and 52. The secondary outcomes were changes in the HBI and C-reactive protein (CRP) values at weeks 8, 26, and 52 from baseline and the normalization of CRP in patients with initially abnormal values. Results: Totally, 140 patients who had previously received at least one anti-TNF- agent were enrolled; 40.0% received two anti-TNF- agents and 20.0% received vedolizumab. At baseline, 108 patients (77.1%) had HBI scores of >4; of these, 56.5% and 58.3% achieved corticosteroidfree clinical remission at weeks 26 and 52, respectively. Significant decreases in HBI and CRP values were observed at weeks 8, 26, and 52 in the entire study cohort (all p < 0.0001). The CRP values were normalized in 34.9%, 37.8%, and 49.3% of the patients by weeks 8, 26, and 52, respectively. The baseline HBI score of "8 was a negative predictor of corticosteroid-free clinical remission at week 52 (odds ratio: 0.21, 95% confidence interval: 0.08–0.56, p # 0.002). The probability of remaining on ustekinumab after 52 weeks was 92.1%. Eleven (7.9%) patients discontinued ustekinumab (three for adverse events). Conclusion: Our study findings confirm the effectiveness and safety of ustekinumab in patients with CD after failure of or intolerance to anti-TNF-a therapy.
crohn’s disease; effectiveness; refractory; ustekinumab
01 Pubblicazione su rivista::01a Articolo in rivista
Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy / Lia Scribano, Maria; Aratari, Annalisa; Neri, Benedetto; Bezzio, Cristina; Balestrieri, Paola; Baccolini, Valentina; Falasco, Giuliano; Camastra, Caterina; Pantanella, Paolo; Monterubbianesi, Rita; Tullio, Alessandro; Saibeni, Simone; Papi, Claudio; Biancone, Livia; Cosintino, Rocco; Faggiani, Roberto. - In: THERAPEUTIC ADVANCES IN GASTROENTEROLOGY. - ISSN 1756-283X. - 15:(2022), pp. 1-13. [10.1177/17562848211072412]
File allegati a questo prodotto
File Dimensione Formato  
Scribano_Effectiveness_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 611.95 kB
Formato Adobe PDF
611.95 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1616726
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact